# PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

> **NCT06157151** · PHASE2 · RECRUITING · sponsor: **Precigen, Inc** · enrollment: 24 (estimated)

## Conditions studied

- Cervical Cancer
- HPV-Related Carcinoma
- HPV-Related Malignancy
- Recurrent Cervical Carcinoma
- Metastatic Cervical Cancer

## Interventions

- **BIOLOGICAL:** PRGN-2009 plus Pembrolizumab

## Key facts

- **NCT ID:** NCT06157151
- **Lead sponsor:** Precigen, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-11
- **Primary completion:** 2026-11-11
- **Final completion:** 2030-11-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06157151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06157151, "PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06157151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*